Robert Ohsfeldt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Ohsfeldt has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Hye-Chung Kum
Population Informatics Lab, Texas A&M University, College Station, Texas
19 shared publications - Amit G. Singal
Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA
17 shared publications - David Washburn
Department of Health Policy and Management, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine , New Orleans, LA
17 shared publications - Nikita Sandeep Wagle
Department of Surveillance, Prevention and Health Services Research American Cancer Society, Inc. Atlanta Georgia USA
17 shared publications - Sulki Park
Population Informatics Lab, Texas A&M University, College Station, TX, United States
17 shared publications - Chau N. Truong
Affiliation School of Public Health Center for Health Care Data, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
2 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by SAGE Publications in Health Services Insights
- Vol. 18
Examining the Cost-Effectiveness of Introducing Patient Navigation Services for Colorectal Cancer Screening Among a Low-Income and Uninsured Population
Background: The colorectal cancer (CRC) screening adherence rate among the uninsured population in the United States (US) is lower than the overall rate across all US adults aged 45 to 75. Objectives: To assess the cost-effectiveness of community health worker (CHW) navigation services promoting CRC screening in a low-income, uninsured population. Methods: Using internal cost and effectiveness data from the Texas A&M Cancer Screening, Training, Education, and Prevention (CSTEP) program, which included 3196 participants, along with published sources such as the U.S. Preventive Services Task Force (USPSTF) recommendations, we estimated incremental cost-effectiveness ratios (ICERs) for CRC screening with CHW navigation versus usual care. The analysis was conducted from a societal perspective using Excel-based modeling in hypothetical cohorts initiating screening at age 45. Results: Under base-case assumptions, a 10 percentage-point improvement in CRC screening attributable to the program increased LYG by 0.160 at an additional lifetime cost of $101, resulting in an ICER of $3098 per LYG. One-way and two-way sensitivity analyses were conducted, varying program costs, screening rate improvements, lifetime CRC costs, and life-years gained (LYG). Conclusion: Our findings underscore the importance of CHW navigation services incorporating CRC screening promotion strategies tailored to uninsured populations to alleviate disparities in colorectal cancer screening and outcomes. Further research should consider the characteristics of uninsured populations, and the applicability of the program targeted for various types of underserved populations.
- 15 December 2025
- Published by SAGE Publications in Health Services Insights
- Vol. 18
Open AccessExamining the Cost-Effectiveness of Introducing Patient Navigation Services for Colorectal Cancer Screening Among a Low-Income and Uninsured Population
Background: The colorectal cancer (CRC) screening adherence rate among the uninsured population in the United States (US) is lower than the overall rate across all US adults aged 45 to 75. Objectives: To assess the cost-effectiveness of community health worker (CHW) navigation services promoting CRC screening in a low-income, uninsured population. Methods: Using internal cost and effectiveness data from the Texas A&M Cancer Screening, Training, Education, and Prevention (CSTEP) program, which included 3196 participants, along with published sources such as the U.S. Preventive Services Task Force (USPSTF) recommendations, we estimated incremental cost-effectiveness ratios (ICERs) for CRC screening with CHW navigation versus usual care. The analysis was conducted from a societal perspective using Excel-based modeling in hypothetical cohorts initiating screening at age 45. Results: Under base-case assumptions, a 10 percentage-point improvement in CRC screening attributable to the program increased LYG by 0.160 at an additional lifetime cost of $101, resulting in an ICER of $3098 per LYG. One-way and two-way sensitivity analyses were conducted, varying program costs, screening rate improvements, lifetime CRC costs, and life-years gained (LYG). Conclusion: Our findings underscore the importance of CHW navigation services incorporating CRC screening promotion strategies tailored to uninsured populations to alleviate disparities in colorectal cancer screening and outcomes. Further research should consider the characteristics of uninsured populations, and the applicability of the program targeted for various types of underserved populations.
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (11) , e011709
Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock
BACKGROUND: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study’s objective was to compare costs between patients treated with and without a Shock Team and determine if the team’s implementation is cost-effective compared with standard of care. METHODS: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations. RESULTS: The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18–92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; P =0.04 and 55.0% versus 40.5%; P =0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations. CONCLUSIONS: The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.
- 1 November 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (11) , e011709
Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock
BACKGROUND: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study’s objective was to compare costs between patients treated with and without a Shock Team and determine if the team’s implementation is cost-effective compared with standard of care. METHODS: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations. RESULTS: The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18–92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; P =0.04 and 55.0% versus 40.5%; P =0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations. CONCLUSIONS: The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Background:Racial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial and ethnic disparities in treatment receipt among patients with HCC in the United States.Methods:We searched Medline, Embase, and CINAHL databases to identify studies published between January 2012 and March 2022 reporting HCC treatment receipt among adult patients with HCC, stratified by race or ethnicity. We calculated pooled odds ratios for HCC treatment using random effects models.Results:We identified 15 studies with 320,686 patients (65.8% White, 13.9% Black, 10.4% Asian, and 8.5% Hispanic). Overall, 33.2% of HCC patients underwent any treatment, and 22.7% underwent curative treatment. Compared with White patients, Black patients had lower odds of any treatment (OR 0.67, 95% CI 0.55–0.81) and curative treatment (OR 0.74, 95% CI 0.71–0.78). Similarly, Hispanic patients had lower pooled odds of curative treatment (OR 0.79, 95% CI 0.73–0.84).Conclusions:There were significant racial and ethnic disparities in HCC treatment receipt, with Black patients having lower odds of receiving any and curative treatment while Hispanic patients having lower odds of curative treatment.Impact:Racial and ethnic differences in treatment receipt serve as an intervention target to reduce disparities in HCC prognosis.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Background:Racial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial and ethnic disparities in treatment receipt among patients with HCC in the United States.Methods:We searched Medline, Embase, and CINAHL databases to identify studies published between January 2012 and March 2022 reporting HCC treatment receipt among adult patients with HCC, stratified by race or ethnicity. We calculated pooled odds ratios for HCC treatment using random effects models.Results:We identified 15 studies with 320,686 patients (65.8% White, 13.9% Black, 10.4% Asian, and 8.5% Hispanic). Overall, 33.2% of HCC patients underwent any treatment, and 22.7% underwent curative treatment. Compared with White patients, Black patients had lower odds of any treatment (OR 0.67, 95% CI 0.55–0.81) and curative treatment (OR 0.74, 95% CI 0.71–0.78). Similarly, Hispanic patients had lower pooled odds of curative treatment (OR 0.79, 95% CI 0.73–0.84).Conclusions:There were significant racial and ethnic disparities in HCC treatment receipt, with Black patients having lower odds of receiving any and curative treatment while Hispanic patients having lower odds of curative treatment.Impact:Racial and ethnic differences in treatment receipt serve as an intervention target to reduce disparities in HCC prognosis.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 2 shows that the pooled proportion for any HCC treatment rate among early-stage HCC patients is 59.6%.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 2 shows that the pooled proportion for any HCC treatment rate among early-stage HCC patients is 59.6%.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 5 shows that there were no significant differences in any (A) or curative treatment (B) receipt between Asian and White patients.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 5 shows that there were no significant differences in any (A) or curative treatment (B) receipt between Asian and White patients.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 4 shows that Black patients with early-stage HCC are significantly less likely to undergo curative treatment than White patients (pooled OR 0.63, 95%CI 0.47 – 0.84).
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 4 shows that Black patients with early-stage HCC are significantly less likely to undergo curative treatment than White patients (pooled OR 0.63, 95%CI 0.47 – 0.84).
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
SES and geographic covariates included in the multivariable analysis of receipt of HCC treatment.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
SES and geographic covariates included in the multivariable analysis of receipt of HCC treatment.